专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010070074A3 EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM 审中-公开
标题翻译：评估药物诱发的情绪失调和自杀的潜在风险：使用专用平台
公开(公告)号：WO2010070074A3
公开(公告)日：2010-10-07
申请号：PCT/EP2009067464
申请日：2009-12-17
申请人： BIOCORTECH , WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT
发明人： WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT
IPC分类号： C12Q1/68 , G01N33/573
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/142 , C12Q2600/158 , G01N33/5014 , G01N33/5058 , G01N33/942 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to in vitro methodsfor the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing of the serotonin 2C receptor (5HTR2C). Finally, the present invention is directed to the kits and tools for the implementation of these methods. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile or the screening of compounds involved in drug development and/or in pharmaceutical compositions.
摘要翻译：本发明涉及用于测定测试化合物的潜在毒性的体外方法。本发明还包括用于选择治疗化合物的体外方法，所述治疗化合物用于治疗与改变ADAR依赖性A至I mRNA编辑血清素2C受体（5HTR2C）的mRNA编辑机制有关的病理学。最后，本发明针对用于实施这些方法的试剂盒和工具。本发明在制药工业中用于分析药物开发中涉及的化合物和/或药物组合物的毒性分布或筛选方面是特别有用的。

2. 发明申请

WO2004011594A8 NOVEL METHOD FOR ANALYZING NUCLEIC ACID AND USE THEREOF FOR EVALUATING THE DEGREE OF MRNA EDITING OF THE SEROTONIN 5-HT2C RECEPTOR 审中-公开
标题翻译：用于分析核酸的新方法及其用于评估SERONON 5-HT2C受体的MRNA编码的程度
公开(公告)号：WO2004011594A8
公开(公告)日：2005-02-24
申请号：PCT/FR0302339
申请日：2003-07-24
申请人： BIOCORTECH , MADJAR JEAN-JACQUES , BERTHOMME HERVE
发明人： MADJAR JEAN-JACQUES , BERTHOMME HERVE
IPC分类号： G01N33/53 , C12M1/00 , C12M1/34 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N37/00
CPC分类号： C12Q1/6827 , C12Q1/6813 , C12Q1/6837 , C12Q2537/143 , C12Q2527/107 , C12Q2525/101 , C12Q2565/131 , C12Q2521/107
摘要： The invention concerns a method for analyzing nucleic acids using a small-size probe array comprising deoxyinosines (dI) instead of deoxyguanosines (dG). The invention also concerns such probe arrays and their use in methods for detecting and/or quantifying target oligonucleotides present in DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) molecules in a sample, in particular mRNA editing rate of the serotonin 5-HT2C receptor (5-HT2C-R). The invention further concerns a biochip or a reactor in liquid medium comprising such probe arrays as well as their uses, in particular for detecting and/or identifying genetic polymorphisms or for determining an mRNA editing rate, whether it is that of a 5-HT2C-R mRNA or any other RNA capable of being edited. The invention also concerns a method based on the isolation of a single strand conformation polymorphism (SSCP) enabling under specific analysis conditions the editing profile and/or rate of an mRNA capable of being edited to be obtained, as well as a method for diagnosing diseases or susceptibility to diseases associated with the degree of edition of an mRNA. Finally, the invention concerns a method for selecting compounds capable of modulating mRNA editing rate, in particular that of 5-HT2C-R, as well as the use of such compounds for preparing a pharmaceutical composition for treating organic fluid.
摘要翻译：本发明涉及使用包含脱氧肌苷（dI）而不是脱氧鸟苷（dG）的小尺寸探针阵列分析核酸的方法。本发明还涉及这种探针阵列及其在检测和/或定量样品中存在于DNA（脱氧核糖核酸）或RNA（核糖核酸））分子中的靶寡核苷酸的方法中的用途，特别是5-羟色胺5-HT 2C受体的mRNA编辑速率（5-HT2C-R）。本发明还涉及包含这种探针阵列的液体培养基中的生物芯片或反应器，以及它们的用途，特别是用于检测和/或鉴定遗传多态性或用于确定mRNA编辑速率，无论是5-HT 2C- R mRNA或能够编辑的任何其他RNA。本发明还涉及一种基于分离单链构象多态性（SSCP）的方法，其能够在特定分析条件下使得能够获得编辑的mRNA的编辑谱和/或速率以及用于诊断疾病的方法或对与mRNA的编程程度相关的疾病的易感性。最后，本发明涉及一种选择能够调节mRNA编辑速率的化合物，特别是5-HT 2C-R的化合物的方法，以及这些化合物在制备用于治疗有机液体的药物组合物中的用途。

3. 发明申请

WO2008152146A1 PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS 审中-公开
标题翻译：包含表达5HTR2C和/或ADARS的细胞的外周组织样品作为改变5HTR2C MRNA编码机制的标记及其应用
公开(公告)号：WO2008152146A1
公开(公告)日：2008-12-18
申请号：PCT/EP2008/057519
申请日：2008-06-13
申请人： BIOCORTECH , WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent , MANN, John
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent , MANN, John
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/6896 , G01N33/942
摘要： The present invention relates to an in vitro method for predicting a pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing, particularly the serotonin 2C receptor (5HTR2C), in a patient from a peripherical tissue sample containing cells expressing said mRNA, such as the 5HTR2C mRNA, and/or adenosine deaminases acting on RNA (ADARs), such as skin and/or blood tissue sample. The present invention further comprises a method for identifying if an agent is capable of in vivo modifying the editing of the 5HTR2C mRNA in brain tissue or to control the efficiency of a drug intended to prevent or to treat a pathology related to an alteration of the mechanism of the 5HTR2C mRNA editing brain tissue, these methods comprising the implementation of said peripherical tissue markers. In a particular aspect, the present invention relates to such methods wherein the 5HTR2C mRNA editing rate or profile, when it is necessary, is determined by a single strand conformation polymorphism (SSCP) method after amplification by a PCR, preferably by a nested PCR, of the specific mRNA fragment containing the edition sites, making it possible, under given analytical conditions, to obtain the editing rate and/or profile of this edited 5HTR2C mRNA from said peripherical tissue. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR.
摘要翻译：本发明涉及一种用于预测来自外周组织样品的患者中ADAR依赖性A至I mRNA编辑的mRNA编辑，特别是5-羟色胺2C受体（5HTR2C）的mRNA编辑的机制的改变的病理学的体外方法含有表达所述mRNA的细胞，例如5HTR2C mRNA，和/或作用于RNA（ADAR）的腺苷脱氨酶，例如皮肤和/或血液组织样品。本发明还包括用于鉴定药物是否能够体内修饰脑组织中的5HTR2C mRNA的编辑或控制旨在预防或治疗与机制改变有关的病理学的效力的方法的5HTR2C mRNA编辑脑组织，这些方法包括实施所述外周组织标记物。在特定方面，本发明涉及这样的方法，其中当需要时，通过PCR扩增后优选通过巢式PCR，通过单链构象多态性（SSCP）方法确定5HTR2C mRNA编辑速率或分布，的具有编码位点的特异性mRNA片段，使得在给定的分析条件下可以从所述外周组织获得该编辑的5HTR2C mRNA的编辑率和/或分布。最后，本发明涉及在所述巢式PCR中实施的特定核酸引物。

4. 发明申请

WO2004011594A3 NOVEL METHOD FOR ANALYZING NUCLEIC ACID ET USE THEREOF FOR EVALUATING THE DEGREE OF MRNA EDITING OF THE SEROTONIN 5-HT2C RECEPTOR 审中-公开
标题翻译：分析核酸用于评估血清素5-HT2C受体MRNA编辑程度的新方法
公开(公告)号：WO2004011594A3
公开(公告)日：2004-08-12
申请号：PCT/FR0302339
申请日：2003-07-24
申请人： BIOCORTECH , MADJAR JEAN-JACQUES , BERTHOMME HERVE
发明人： MADJAR JEAN-JACQUES , BERTHOMME HERVE
IPC分类号： G01N33/53 , C12M1/00 , C12M1/34 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N37/00
CPC分类号： C12Q1/6827 , C12Q1/6813 , C12Q1/6837 , C12Q2537/143 , C12Q2527/107 , C12Q2525/101 , C12Q2565/131 , C12Q2521/107
摘要： The invention concerns a method for analyzing nucleic acids using a small-size probe array comprising deoxyinosines (dI) instead of deoxyguanosines (dG). The invention also concerns such probe arrays and their use in methods for detecting and/or quantifying target oligonucleotides present in DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) molecules in a sample, in particular mRNA editing rate of the serotonin 5-HT2C receptor (5-HT2C-R). The invention further concerns a biochip or a reactor in liquid medium comprising such probe arrays as well as their uses, in particular for detecting and/or identifying genetic polymorphisms or for determining an mRNA editing rate, whether it is that of a 5-HT2C-R mRNA or any other RNA capable of being edited. The invention also concerns a method based on the isolation of a single strand conformation polymorphism (SSCP) enabling under specific analysis conditions the editing profile and/or rate of an mRNA capable of being edited to be obtained, as well as a method for diagnosing diseases or susceptibility to diseases associated with the degree of edition of an mRNA. Finally, the invention concerns a method for selecting compounds capable of modulating mRNA editing rate, in particular that of 5-HT2C-R, as well as the use of such compounds for preparing a pharmaceutical composition for treating organic fluid.
摘要翻译：本发明涉及使用包含脱氧肌苷（dI）而不是脱氧鸟苷（dG）的小型探针阵列来分析核酸的方法。本发明还涉及这样的探针阵列及其在用于检测和/或定量样品中的DNA（脱氧核糖核酸）或RNA（核糖核酸）分子中存在的靶寡核苷酸的方法中的用途，特别是血清素5-HT 2C受体的mRNA编辑速率（5-HT2C-R）。本发明进一步涉及在液体介质中的生物芯片或反应器，其包含这样的探针阵列以及它们的用途，特别是用于检测和/或鉴定遗传多态性或确定mRNA编辑速率，不管它是5-HT2C- R mRNA或任何其他能够被编辑的RNA。本发明还涉及基于分离单链构象多态性（SSCP）的方法，所述单链构象多态性能够在特定分析条件下使得能够被编辑的mRNA的编辑概况和/或速率得以获得，以及用于诊断疾病的方法或对与mRNA编辑程度相关的疾病的易感性。最后，本发明涉及用于选择能够调节mRNA编辑速率的化合物，特别是5-HT2C-R的化合物的方法，以及这种化合物用于制备用于处理有机流体的药物组合物的用途。

5. 发明申请

WO2011161253A1 EDITING PROFILING OF PDE8A PRE -MRNA : USE AS SPECIFIC BIOMARKER OF ADARS ACTIVITIES IN HUMAN TISSUES TO DIAGNOSE AND TO PREDICT AND ASSESS THERAPEUTIC EFFICACY AND/OR EFFICIENCY OR POTENTIAL DRUG SIDE EFFECTS 审中-公开
标题翻译： PDE8A PRE-MRNA的编辑概况：用作人体组织中ADARS活动的特定生物标志物，用于诊断和预测和评估治疗效果和/或效率或潜在药物副作用
公开(公告)号：WO2011161253A1
公开(公告)日：2011-12-29
申请号：PCT/EP2011/060644
申请日：2011-06-24
申请人： BIOCORTECH , WEISSMANN, Dinah , PUJOL, Jean-François , CAVAREC, Laurent , VINCENT, Laurent
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , CAVAREC, Laurent , VINCENT, Laurent
IPC分类号： C12Q1/68 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q1/34 , C12Q2600/106 , C12Q2600/136 , C12Q2600/142 , C12Q2600/158 , G01N33/5023 , G01N2333/978 , G01N2800/28 , G01N2800/2821 , G01N2800/2857 , G01N2800/30 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to the use of the editing profile of PDE8A pre-mRNA as a specific bio marker of ADARs activities in evolved primate, particularly in Human tissues. The present invention also relates to an in vitro method for predicting in Human an alteration of the mechanism of the ADARs catalysed pre-mRNA editing of target genes, by analysing the PDE8A pre-mRNA editing profile in a peripheral tissue sample containing cells expressing said PDE8A pre-mRNA, such as blood sample. The present invention is also directed to an in vitro method for the screening of potential therapeutic compound and to predict and assess therapeutic efficacy and/or efficiency or to diagnose potential severe brain or peripheral drug side effects implementing said PDE8A pre-mRNA editing profile as specific biomarker. The present invention is further directed to a method for determining the PDE8A pre-mRNA editing profile in Human, particularly by capillary electrophoresis single-strand conformation polymorphism (CE-SSCP) method after amplification by a nested PCR. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR and kit comprising such sets of primers and human cells capable of expressing PDE8A and ADARs.
摘要翻译：本发明涉及PDE8A前mRNA的编辑概况在进化灵长类动物中特别是ADARs活性的特异性生物标记物的使用，特别是在人组织中。本发明还涉及通过在含有表达所述PDE8A的细胞的外周组织样品中分析PDE8A前mRNA编码谱的方法，在人类中预测ADAR催化的靶基因前mRNA编辑机制的改变前mRNA，如血液样品。本发明还涉及用于筛选潜在治疗化合物并预测和评估治疗功效和/或效率或用于诊断实施所述PDE8A前mRNA编辑简档作为具体的潜在严重脑或外周药物副作用的体外方法生物标志物。本发明还涉及一种通过巢式PCR扩增后，特别是通过毛细管电泳单链构象多态性（CE-SSCP）方法测定人类PDE8A前mRNA编码特征的方法。最后，本发明涉及在所述巢式PCR中实施的特定核酸引物和包含能够表达PDE8A和ADAR的这样一组引物和人细胞的试剂盒。

6. 发明申请

WO2005103047A8 DERIVATIVES OF 14.15-DIHYDRO 20.21-DINOREBURNAMENIN-14-OL, AND APPLICATIONS THEREOF 审中-公开
标题翻译： 14.15-二氢O O O O O IN IN IN IN IN IN IN IN IN IN IN IN IN IN IN IN OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF OF
公开(公告)号：WO2005103047A8
公开(公告)日：2006-11-16
申请号：PCT/FR2005000902
申请日：2005-04-14
申请人： BIOCORTECH , CIAPETTI PAOLA , DEYON LAURENCE , WERMUTH CAMILLE-GEORGES , PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
发明人： CIAPETTI PAOLA , DEYON LAURENCE , WERMUTH CAMILLE-GEORGES , PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
IPC分类号： C07D461/00 , A61K31/437 , A61P25/18 , A61P25/24
CPC分类号： C07D461/00
摘要： The invention relates to novel derivatives of 14,15-dihydro 20,21 dinoreburnamenin-14-ol, having formula (I), in which R represents a radical -AR', wherein A represents a heteroatom and R' represents a group selected from the group comprising alkyl radicals at C 1 -C 6 , alkenyls at C 1 -C 6 , alkynyls at C 1 -C 6 , aralkyls; esters having formula -R 1 -CO-O-R 2 ; amides having formula -R 3 -CO-NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine having formula -NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures of same. The invention also relates to the use of said novel derivatives for the preparation of a pharmaceutical composition which is intended, in particular, for the treatment and/or prevention of depression, sleep/wake cycle disorders and symptomatic frontal disorders in cognitive components among humans.
摘要翻译：本发明涉及具有式（I）的14,15-二氢20,21二辛烷亚胺-14-醇的新衍生物，其中R表示一个自由基-AR'，其中A表示杂原子，R'表示选自 C 1 -C 6烷基，C 1 -C 6亚烷基，C 1 -C 6亚烷基，C 1 -C 6亚烷基，C 1 -C 6亚烷基， C 1 -C 6 - 芳烷基; 具有式-R 1 -CO-O-R 2的酯; 具有式-R 3 -CO-NZY的酰胺，其中Y和Z一起可以形成任选被一个或多个烷基取代的环烷基或杂环基; 选自由至少一个具有式-NZY的胺取代的烷基，烯基或炔基的基团; 或其药学上可接受的盐之一，包括其异构体，对映体和非对映异构体及其混合物。本发明还涉及所述新型衍生物用于制备药物组合物的用途，该药物组合物特别用于治疗和/或预防人类中认知成分中的抑郁症，睡眠/觉醒周期障碍和症状性正面疾病。

7. 发明专利

CA2493264C NOUVELLE METHODE D'ANALYSE D'ACIDE NUCLEIQUE ET SON UTILISATION POUR EVALUER LE DEGRE D'EDITION D'UN ARNM, NOTAMMENT CELUI DU RECEPTEUR 5-HT2C DE LA SEROTONINE 未知
公开(公告)号：CA2493264C
公开(公告)日：2014-02-18
申请号：CA2493264
申请日：2003-07-24
申请人： BIOCORTECH
发明人： MADJAR JEAN-JACQUES , BERTHOMME HERVE
IPC分类号： C12Q1/68 , G01N33/53 , C12M1/00 , C12M1/34 , C12N15/09 , C12Q1/02 , G01N37/00
摘要： La présente invention se rapporte à une méthode d'analyse des acides nucléiques mettant en oeuvre un jeu de sondes de petite taille incluant des désoxyinosines (dl) à la place de désoxyguanosines (dG). L'invention comprend également de tels jeux de sondes ainsi que leur utilisation dans des procédés de détection et/ou de quantification d'oligonucléotides cibles présents dans des molécules d'ADN (acide désoxyribonucléique) ou d'ARN (acide ribonucléique) dans un échantillon, notamment la détermination du taux d'édition de l'ARN messager (ARNm) du récepteur 5-HT2c (5-HT2c-R) de la sérotonine. L'invention est aussi relative à une biopuce ou à un réacteur en milieu liquide comprenant de tels jeux de sondes ainsi que leurs utilisations, notamment pour la détection et/ou l'identification de polymorphismes génétiques ou pour la détermination du taux d'édition d'un ARNm, que ce soit celui de l'ARNm du 5-HT2c-R ou de tout autre ARN susceptible d'être édité. La présente invention a également pour objet une méthode fondée sur la mise en évidence de polymorphisme de conformation de l'ADN simple brin (SSCP) permettant dans des conditions données d'analyse d'obtenir le profil et/ou le taux d'édition d'un ARNm susceptible d'être édité, ainsi qu'une méthode de diagnostic de maladies ou de susceptibilité à des maladies associées au degré d'édition d'un ARNm. La présente invention a aussi pour objet une méthode de sélection de composés capables de moduler le taux d'édition de l'ARNm, notamment celui du 5-HT2c R, ainsi que l'utilisation de tels composés pour la préparation d'une composition pharmaceutique destinée au traitement de l'humeur.

8. 发明专利

AT488516T 未知
公开(公告)号：AT488516T
公开(公告)日：2010-12-15
申请号：AT05757149
申请日：2005-04-14
申请人： BIOCORTECH
发明人： CIAPETTI PAOLA , DEYON LAURENCE , WERMUTH CAMILLE-GEORGES , PUJOL JEAN-FRANCOIS , WEISSMANN DINAH
IPC分类号： C07D461/00 , A61K31/437 , A61P25/18 , A61P25/24
摘要： The invention relates to novel derivatives of 14,15-dihydro 20,21-dinoreburnamenin-14-ol, having formula (I) in which R represents a radical -AR' wherein A represents a heteroatom and R' represents a group selected from the group comprising linear or branched C 1 -C 6 alkyl radicals, C 2 -C 6 alkenyls, C 2 -C 6 alkynyls, arylalkyls; esters comprising the formula -R 1 - CO-O-R 2 ; amides comprising the formula -R 3 -CO-NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine with formula -NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures thereof. The invention also relates to the use of the novel derivatives for the preparation of a pharmaceutical composition which is intended, in particular, for the treatment and/or prevention of depression, sleep-wake cycle disorders and symptomatic frontal disorders in cognitive components among humans.

9. 发明专利

CA2493264A1 METHODE D'ANALYSE D'ACIDES NUCLEIQUES ET SON UTILISATION POUR EVALUER LE DEGRE D'EDITION DE L`ARNM DU RECEPTEUR 5-HT2C DE LA SEROTONINE 未知
公开(公告)号：CA2493264A1
公开(公告)日：2004-02-05
申请号：CA2493264
申请日：2003-07-24
申请人： BIOCORTECH
发明人： MADJAR JEAN-JACQUES , BERTHOMME HERVE
IPC分类号： G01N33/53 , C12M1/00 , C12M1/34 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N37/00
摘要： La présente invention se rapporte à une méthode d'analyse des acides nucléiques mettant en oeuvre un jeu de sondes de petite taille incluant des désoxyinosines (dl) à la place de désoxyguanosines (dG). L'invention compren d également de tels jeux de sondes ainsi que leur utilisation dans des procédé s de détection et/ou de quantification d'oligonucléotides cibles présents dans des molécules d'ADN (acide désoxyribonucléique) ou d'ARN (acide ribonucléiqu e) dans un échantillon, notamment la détermination du taux d'édition de l'ARN messager (ARNm) du récepteur 5-HT2c (5-HT2c-R) de la sérotonine. L'invention est aussi relative à une biopuce ou à un réacteur en milieu liquide comprena nt de tels jeux de sondes ainsi que leurs utilisations, notamment pour la détection et/ou l'identification de polymorphismes génétiques ou pour la détermination du taux d'édition d'un ARNm, que ce soit celui de l'ARNm du 5- HT2c-R ou de tout autre ARN susceptible d'être édité. La présente invention a également pour objet une méthode fondée sur la mise en évidence de polymorphisme de conformation de l'ADN simple brin (SSCP) permettant dans de s conditions données d'analyse d'obtenir le profil et/ou le taux d'édition d'u n ARNm susceptible d'être édité, ainsi qu'une méthode de diagnostic de maladie s ou de susceptibilité àdes maladies associées au degré d'édition d'un ARNm. L a présente invention a aussi pour objet une méthode de sélection de composés capables de moduler le taux d'édition de l'ARNm, notamment celui du 5-HT2c R , ainsi que l'utilisation de tels composés pour la préparation d'une compositi on pharmaceutique destinée au traitement de l'humeur.

10. 发明公开

EP1727543A1 UTILISATION DU 14,15-DIHYDRO 20,21-DINOREBURNAMENIN14-OL POUR TRAITER ET/OU PREVENIR LES DEPRESSIONS MAJEURES ET LES DESORDRES DU CYCLE VEILLE-SOMMEIL 有权
标题翻译： 14,15二氢20,21-dinoreburnamenine-14-OL用于治疗和防止严重抑郁症的用途
公开(公告)号：EP1727543A1
公开(公告)日：2006-12-06
申请号：EP05717501.0
申请日：2005-01-27
申请人： Biocortech
发明人： PUJOL, Jean-François , WEISSMANN, Dinah
IPC分类号： A61K31/437
CPC分类号： A61K31/4375
摘要： The invention relates to a novel therapeutic use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment of serious depression in humans, particularly for the treatment of patients resistant to conventional anti-depressant treatments and for treatment of sleep/waking cycle disorders.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式